Extended median overall survival of 8.5 months compared to
placebo (24 months versus 16 months)
Currently the only treatment (chemotherapy) with a survival
benefit approved for advanced prostate cancer extends median
overall survival by an average of approximately 2-3 months
Phase II study achieved a p-value of 0.006
Reduced the risk of death by 44% compared to placebo
(HR=0.559)
Off-the-shelf vial vaccine that does not require complex
individualised therapy
Recombinant viral vaccine that can be manufactured and
reproduced easily. Other prostate cancer vaccine candidates are
cell based and therefore difficult to scale, produce and
standardize
Very favourable safety and tolerability profile
Holds the promise of moving into larger patient populations in
earlier stages of the disease
